Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393

Clinical Immunology

Volumn 125, Issue 3, 2007, Pages 318-327

  Allam, Mustapha ^a   Julien, Nathalie ^a   Zacharie, Boulos ^a   Penney, Christopher ^a   Gagnon, Lyne ^a  

^a ProMetic Life Sciences Inc   (Canada)

Author keywords

Concanavalin A; IFN ; IL 2; Immunostimulant; PBI 1393; Th1 cytokine

Indexed keywords

GAMMA INTERFERON; HYPOXANTHINE DERIVATIVE; INTERLEUKIN 2; MESSENGER RNA; PBI 1393; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TH1 CELL;

ARGININE; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENES, FOS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PURINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TH1 CELLS; TRANSCRIPTION FACTOR AP-1;

EID: 36148956592     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.07.017     Document Type: Article

References (48)

1. Morgan D.A., Ruscetti F.W., and Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 193 (1976) 1007-1008
2. Smith K.A. Interleukin-2: inception, impact, and implications. Science 240 (1988) 1169-1176
3. Ibayashi Y., Tokuda Y., Saks E.R., Sarna G.P., and Golub S.H. In vivo and in vitro activation of NK cytotoxicity with IL-2. Prog. Clin. Biol. Res. 244 (1987) 275-285
4. Zhu H.G., Zollner T.M., Klein-Franke A., and Anderer F.A. Activation of human monocyte/macrophage cytotoxicity by IL-2/IFN gamma is linked to increased expression of an antitumor receptor with specificity for acetylated mannose. Immunol. Lett. 38 (1993) 111-119
5. Ferrante A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol. Ser. 57 (1992) 417-436
6. Dillman R.O. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother. 9 (1994) 183-209
7. McDermott D.F., and Atkins M.B. Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. 4 (2004) 455-468
8. Cooney M.M., Remick S.C., and Vogelzang N.J. Promising systemic therapy for renal cell carcinoma. Curr. Treatm. Opt. Oncol. 6 (2005) 357-365
9. Young H.A., and Hardy K.J. Interferon-gamma: producer cells, activation stimuli, and molecular genetic regulation. Pharmacol. Ther. 45 (1990) 137-151
10. Bradley L.M., Dalton D.K., and Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J. Immunol. 157 (1996) 1350-1358
11. Wenner C.A., Guler M.L., Macatonia S.E., O'Garra A., and Murphy K.M. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J. Immunol. 156 (1996) 1442-1447
12. Murray H.W. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am. J. Med. 97 (1994) 459-467
13. Aoki N., and Xing Z. Use of cytokines in infection. Expert Opin. Emerg. Drugs 9 (2004) 223-236
14. Gupta S.L. Regulation of cellular gene expression by interferon-gamma: involvement of multiple pathways. Int. J. Cell Cloning 8 Suppl. 1 (1990) 92-102
15. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., and Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265 (1994) 106-109
16. Mouy R., Seger R., Bourquin J.P., Veber F., Blanche S., Griscelli C., and Fischer A. Interferon gamma for chronic granulomatous disease. N. Engl. J. Med. 325 (1991) 1516-1517
17. Mattson K., Niiranen A., Pyrhonen S., Farkkila M., and Cantell K. Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity. Acta Oncol. 30 (1991) 607-610
18. Loftis J.M., and Hauser P. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 82 (2004) 175-190
19. Hadden J.W. Immunostimulants. Immunol. Today 14 (1993) 275-280
20. Khoo S.K., Whitaker S.V., Jones I.S., and Thomas D.A. Levamisole as adjuvant to chemotherapy of ovarian cancer. Results of a randomized trial and 4-year follow-up. Cancer 54 (1984) 986-990
21. Arya R., Rolan P.E., Wootton R., Posner J., and Bellingham A.J. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br. J. Haematol. 93 (1996) 817-821
22. Sosa M., Saha A.R., Wang Y., Coto J., Giner-Sorolla A., Hadden E.M., and Hadden J.W. Potentiation of immune responses in mice by a new inosine derivative-methyl inosine monophosphate (MIMP). Int. J. Immunopharmacol. 14 (1992) 1259-1266
23. Zacharie B., Gagnon L., Attardo G., Connolly T.P., St-Denis Y., and Penney C.L. Synthesis and activity of 6-substituted purine linker amino acid immunostimulants. J. Med. Chem. 40 (1997) 2883-2894
24. Kadhim S., Penney C., Lagraoui M., Heibein J., Attardo G., Zacharie B., Connolly T., and Gagnon L. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide. Int. J. Immunopharmacol. 22 (2000) 659-671
25. Puntschart A., Wey E., Jostarndt K., Vogt M., Wittwer M., Widmer H.R., Hoppeler H., and Billeter R. Expression of fos and jun genes in human skeletal muscle after exercise. Am. J. Physiol.: Cell Physiol. 274 (1998) 129-137
26. Patra A.K., Na S.Y., and Bommhardt U. Active protein kinase B regulates TCR responsiveness by modulating cytoplasmic-nuclear localization of NFAT and NF-kappa B proteins. J. Immunol. 172 (2004) 4812-4820
27. Gaffen S.L., and Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004) 109-123
28. Gu J.J., Harriss J.V., Ozato K., and Gottlieb P.D. Induction by concanavalin A of specific mRNAs and cytolytic function in a CD8-positive T cell hybridoma. J. Immunol. 153 (1994) 4408-4417
29. Jain J., Valge-Archer V.E., and Rao A. Analysis of the AP-1 sites in the IL-2 promoter. J. Immunol. 148 (1992) 1240-1250
30. Smith K.A. T-cell growth factor. Immunol. Rev. 51 (1980) 337-357
31. Bonjardim C.A. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses- and viruses counteract IFN action. Microbes Infect. 7 (2005) 569-578
32. Weiss A., Imboden J., Wiskocil R., and Stobo J. The role of T3 in the activation of human T cells. J. Clin. Immunol. 4 (1984) 165-173
33. Weiss A., Wiskocil R.L., and Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133 (1984) 123-128
34. Hardy K.J., Peterlin B.M., Atchison R.E., and Stobo J.D. Regulation of expression of the human interferon gamma gene. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 8173-8177
35. Hodge D.L., Martinez A., Julias J.G., Taylor L.S., and Young H.A. Regulation of nuclear gamma interferon gene expression by interleukin 12 (IL-12) and IL-2 represents a novel form of posttranscriptional control. Mol. Cell. Biol. 22 (2002) 1742-1753
36. Khatri V.P., Fehniger T.A., Baiocchi R.A., Yu F., Shah M.H., Schiller D.S., Gould M., Gazzinelli R.T., Bernstein Z.P., and Caligiuri M.A. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 101 (1998) 1373-1378
37. Gibellini D., Caputo A., Capitani S., La Placa M., and Zauli G. Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. Blood 89 (1997) 1654-1664
38. Gibellini D., Re M.C., Ponti C., Celeghini C., Melloni E., La Placa M., and Zauli G. Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells. Br. J. Haematol. 112 (2001) 663-670
39. Wolberg G., Zimmerman T.P., Hiemstra K., Winston M., and Chu L.C. Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science 187 (1975) 957-959
40. Antonysamy M.A., Moticka E.J., and Ramkumar V. Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes. J. Immunol. 155 (1995) 2813-2821
41. Huang S., Apasov S., Koshiba M., and Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90 (1997) 1600-1610
42. Mirabet M., Herrera C., Cordero O.J., Mallol J., Lluis C., and Franco R. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J. Cell. Sci. 112 Pt. 4 (1999) 491-502
43. Erdmann A.A., Gao Z.G., Jung U., Foley J., Borenstein T., Jacobson K.A., and Fowler D.H. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105 (2005) 4707-4714
44. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9 (1988) 222-229
45. Li L., Yee C., and Beavo J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283 (1999) 848-851
46. Abrahamsen H., Baillie G., Ngai J., Vang T., Nika K., Ruppelt A., Mustelin T., Zaccolo M., Houslay M., and Tasken K. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J. Immunol. 173 (2004) 4847-4858
47. Vang T., Torgersen K.M., Sundvold V., Saxena M., Levy F.O., Skalhegg B.S., Hansson V., Mustelin T., and Tasken K. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J. Exp. Med. 193 (2001) 497-507
48. Fraiser L.H., Kanekal S., and Kehrer J.P. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 42 (1991) 781-795